South San Francisco-based Coda Biotherapeutics Inc, a preclinical-stage biopharmaceutical company, has raised a total of $34 million in funding. Versant Ventures was the lead investor in Coda’s latest funding round.
Source: Press Release
Coda Biotherapeutics racks up funding
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.